Galactomannan-amphotericin B conjugate: Synthesis and biological activity

Shimon Farber, Diana Ickowicz, Edward Sionov, Sarah Kagan, Itzhack Polacheck, Abraham J. Domb*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Polysaccharide conjugated amphotericin B (AmB) was synthesized by conjugation of AmB to oxidized galactomannan (GM) by reductive amination and tested for antifungal activity. AmB conjugates were investigated for their ability to inhibit Candida albicans growth. Antifungal efficiency of the synthetic AmB-GM depends on both, AmB content and duration of exposure. The most potent compound was a conjugate which contains 40% AmB with minimal inhibition concentration of 0.25 mg/l. In vitro toxicity analysis revealed that conjugates with 20, 30, and 40% w/w AmB content have no hemolytic effect and no influence on the viability of the VERO kidney cells. Furthermore, maximal tolerant dose (MTD) of the conjugate was determined in vivo and found to be 60 mg/kg (equivalent to AmB), while commercial Fungizone® demonstrated increased toxicity of 3 mg/kg on mice model.

Original languageEnglish
Pages (from-to)119-125
Number of pages7
JournalPolymers for Advanced Technologies
Volume22
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • Amphotericin B
  • Antifungal activity
  • Conjugate
  • Galactomannan

Fingerprint

Dive into the research topics of 'Galactomannan-amphotericin B conjugate: Synthesis and biological activity'. Together they form a unique fingerprint.

Cite this